Clinical Trial Update: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating a combination of oregovomab and niraparib in platinum-sensitive recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Oregovomab (oregovomab)

Snippet

Sponsor: CanariaBio Inc. | Conditions: Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary | Phase 2 | Status: ACTIVE_NOT_RECRUITING